Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea

Published: May 15, 2020
Abstract
The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti-programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients...
Paper Details
Title
Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Published Date
May 15, 2020
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.